Abeona Therapeutics Inc. (ABEO) Stock Rating Lowered by Zacks Investment Research, Report finds

Abeona Therapeutics Inc. (ABEO) Stock Rating Lowered by Zacks Investment Research, Report finds

Abeona Therapeutics Inc. (NASDAQ:ABEO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.

According to Zacks, “Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. “

A number of other brokerages have also recently weighed in on ABEO. Rodman & Renshaw restated a “buy” rating and set a $20.00 price objective (up from $17.00) on shares of Abeona Therapeutics in a research note on Tuesday. FBR & Co reiterated an “outperform” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research report on Thursday, December 1st. Cantor Fitzgerald reiterated a “buy” rating and issued a $21.00 price target on shares of Abeona Therapeutics in a research report on Friday, October 21st. Maxim Group reiterated a “buy” rating and issued a $14.00 price target on shares of Abeona Therapeutics in a research report on Thursday, December 15th. Finally, Jefferies Group LLC began coverage on shares of Abeona Therapeutics in a research report on Friday, January 6th. They issued a “buy” rating and a $11.00 price target on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $15.18.

Abeona Therapeutics (NASDAQ:ABEO) traded down 4.67% during midday trading on Wednesday, hitting $5.10. 403,703 shares of the company traded hands. Abeona Therapeutics has a 12-month low of $2.05 and a 12-month high of $9.44. The stock has a 50 day moving average price of $5.07 and a 200-day moving average price of $5.38. The company’s market cap is $203.79 million.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Thursday, November 10th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.11. Abeona Therapeutics had a negative net margin of 2,029.60% and a negative return on equity of 26.65%. Analysts expect that Abeona Therapeutics will post ($0.59) EPS for the current year.

Large investors have recently modified their holdings of the company. RTW Investments LLC acquired a new stake in shares of Abeona Therapeutics during the third quarter valued at approximately $116,000. Ardsley Advisory Partners acquired a new stake in shares of Abeona Therapeutics during the third quarter valued at approximately $120,000. Baker BROS. Advisors LP acquired a new stake in shares of Abeona Therapeutics during the third quarter valued at approximately $610,000. Highbridge Capital Management LLC acquired a new stake in shares of Abeona Therapeutics during the third quarter valued at approximately $1,591,000. Finally, Knoll Capital Management LP acquired a new stake in shares of Abeona Therapeutics during the third quarter valued at approximately $8,036,000. Hedge funds and other institutional investors own 17.43% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment

Abeona Therapeutics Inc. (ABEO) Stock Rating Lowered by Zacks Investment Research

Abeona Therapeutics Inc. (ABEO) Stock Rating Lowered by Zacks Investment Research

Abeona Therapeutics Inc. (NASDAQ:ABEO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.

According to Zacks, “Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. “

A number of other brokerages have also recently weighed in on ABEO. Rodman & Renshaw restated a “buy” rating and set a $20.00 price objective (up from $17.00) on shares of Abeona Therapeutics in a research note on Tuesday. FBR & Co reiterated an “outperform” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research report on Thursday, December 1st. Cantor Fitzgerald reiterated a “buy” rating and issued a $21.00 price target on shares of Abeona Therapeutics in a research report on Friday, October 21st. Maxim Group reiterated a “buy” rating and issued a $14.00 price target on shares of Abeona Therapeutics in a research report on Thursday, December 15th. Finally, Jefferies Group LLC began coverage on shares of Abeona Therapeutics in a research report on Friday, January 6th. They issued a “buy” rating and a $11.00 price target on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $15.18.

Abeona Therapeutics (NASDAQ:ABEO) traded down 4.67% during midday trading on Wednesday, hitting $5.10. 403,703 shares of the company traded hands. Abeona Therapeutics has a 12-month low of $2.05 and a 12-month high of $9.44. The stock has a 50 day moving average price of $5.07 and a 200-day moving average price of $5.38. The company’s market cap is $203.79 million.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Thursday, November 10th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.11. Abeona Therapeutics had a negative net margin of 2,029.60% and a negative return on equity of 26.65%. Analysts expect that Abeona Therapeutics will post ($0.59) EPS for the current year.

Large investors have recently modified their holdings of the company. RTW Investments LLC acquired a new stake in shares of Abeona Therapeutics during the third quarter valued at approximately $116,000. Ardsley Advisory Partners acquired a new stake in shares of Abeona Therapeutics during the third quarter valued at approximately $120,000. Baker BROS. Advisors LP acquired a new stake in shares of Abeona Therapeutics during the third quarter valued at approximately $610,000. Highbridge Capital Management LLC acquired a new stake in shares of Abeona Therapeutics during the third quarter valued at approximately $1,591,000. Finally, Knoll Capital Management LP acquired a new stake in shares of Abeona Therapeutics during the third quarter valued at approximately $8,036,000. Hedge funds and other institutional investors own 17.43% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment